Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Supernus Pharmaceuticals Fourth Quarter and Full Year 2025 Financial Results Conference Call.
Supernus Pharmaceuticals Inc. (SUPN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 2,764,000 | $137,370,800 | -3% | 1.63% |
| 2. | Millennium Management Israel Englander | 2,640,066 | $131,211,280 | +663% | 0.06% |
| 3. | Point72 Asset Management Steve Cohen | 2,264,800 | $112,560,560 | +29% | 0.13% |
| 4. | Renaissance Technologies Jim Simons | 1,732,522 | $86,106,343 | -1% | 0.13% |
| 5. | D E Shaw D. E. Shaw | 707,982 | $35,186,705 | -28% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.39 | 7,200 | $189,982.08 | 465,141 | 2019-08-23 | Filing | |
| $5.65 | 15,000 | $84,795.00 | 25,000 | 2013-03-22 | Filing | |
| $5.26 | 10,000 | $52,640.00 | 10,000 | 2013-03-20 | Filing | |
| $5.20 | 5,000 | $25,975.00 | 5,000 | 2013-03-20 | Filing | |
| $5.17 | 5,000 | $25,860.00 | 5,000 | 2013-03-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.48 | 412 | $20,797.76 | 17,044 | 2026-03-18 | Filing | |
| $49.55 | 6,838 | $338,822.90 | 17,456 | 2026-03-18 | Filing | |
| $50.73 | 22,290 | $1,130,771.70 | 17,044 | 2026-03-17 | Filing | |
| $49.95 | 27,710 | $1,384,114.50 | 39,334 | 2026-03-17 | Filing | |
| $50.49 | 15,886 | $802,084.14 | 17,044 | 2026-03-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,735,868 | $434,172,640 | 0.01% | |
| 2. | 6,048,496 | $300,610,252 | 0% | |
| 3. | 2,712,341 | $134,804,044 | 0.03% | |
| 4. | 2,307,639 | $114,690,000 | 0.17% | |
| 5. | 2,219,228 | $110,295,632 | 0% |
News See All
Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3
Aristotle Capital Boston, LLC, an investment advisor, released its “Small Cap Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Supernus Pharmaceuticals Third Quarter 2025 Financial Results Conference Call.
Supernus Pharmaceuticals (SUPN) is Benefiting from Its Strength in Financial Position
Third Avenue Management, an investment management company based in New York City, released its “Third Avenue Small-Cap Value Fund” third-quarter 2025 investor letter.
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN)
Third Avenue Management, an investment management company based in New York City, released its “Third Avenue Small-Cap Value Fund” second-quarter 2025 investor letter.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Supernus Pharmaceuticals Second Quarter 2025 Financial Results Conference Call.
10 Best Pharma Stocks to Buy for Long Term Growth
With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is going through a unique trend never seen before.
10 Cash-Rich Small Cap Stocks To Invest In According To Analysts
Small-cap stocks in the US have been under pressure, with the Russell small cap index falling 10% from its November highs as of January 2025.
12 Best Small Cap Pharma Stocks to Buy Now
Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2024 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2024 Earnings Call Transcript February 25, 2025Supernus Pharmaceuticals, Inc. beats earnings expectations.
Hedge Fund Resource Center